Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed multiple myeloma patients: subanalysis of the phase 3 VISTA study

Abstract

This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myeloma ineligible for high-dose therapy who received bortezomib plus melphalan-prednisone.

Keywords

• VISTA trial
• bortezomib
• multiple myeloma
• high-dose therapy
• melphalan-prednisone
• peripheral neuropathy (PN)